Results 71 to 80 of about 2,835 (171)
British Journal of Pharmacology, EarlyView.Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller +3 more
wiley +1 more source
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Brain DisordersClinicians and researchers are showing increased interest in psychedelic-assisted therapy for patients who don't show improvement from using conventional antidepressants.
Matthew Halma, Rakeem Levy, Joseph Varon
doaj +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
, 2023 Psychedelic research became throttled in the 1970s, though the clinical interest for psychedelics has seen a resurgence in the last couple of decades for their application as psychotherapy-adjunct substances used to treat various psychological disorders.
Johansson, Andreas
core +1 more source
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Frontiers in Pharmacology, 2018 Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a ...
Eduardo Ekman Schenberg
doaj +1 more source
Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review
Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 94-108, July 2026.Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović +4 more
wiley +1 more source
MedicinaBackground and Objectives: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited.
Lavinia Hogea +7 more
doaj +1 more source
Brain and Behavior, Volume 16, Issue 6, June 2026.Individuals with treatment‐resistant depression considering psychedelic trial participation were motivated by chronic illness, failed treatments, and hope for a novel intervention, while actively minimizing expectations to guard against disappointment.
Christopher Poppe +3 more
wiley +1 more source
Integrating the Gestalt Model of Self With Psychedelic‐Assisted Psychotherapy
The Journal of Humanistic Counseling, Volume 65, Issue S1, Page S77-S88, May 2026.ABSTRACT This theoretical integration paper employs a conceptual analysis methodology to synthesize the Gestalt model of self‐as‐process with Psychedelic Somatic Interactional Psychotherapy (PSIP). Unlike traditional psychedelic therapy models that defer therapeutic engagement to postsession integration, PSIP emphasizes an active, directive therapeutic
Travis R. Fox
wiley +1 more source
Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users. [PDF]
, 2013 There have been several recent efforts in the UK and the Netherlands to describe the harms of psychoactive substances based on ratings of either experts or drug users.
Noronha, LA +4 more
core